GlassScriptPhysician profile
Shelli Ann Ridge
NPI 1356629356
$5,660.43
in general payments reported to CMS, 2019-2025
36 companies · $892 in 2025
The $892 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $291 · 2021: $94.65 · 2022: $970 · 2023: $1,563 · 2024: $1,115 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,505 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,505.00 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,122.84 | 2021-2025 | |
| Novo Nordisk INC | $992.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $701.23 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Corcept Therapeutics | $474.35 | 2022-2025 | Korlym |
| Lilly USA, LLC | $385.15 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $296.62 | 2019-2024 | |
| Glaxosmithkline, LLC. | $233.08 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Galderma Laboratories, L.P. | $179.12 | 2021-2025 | Dysport |
| Bayer Healthcare Pharmaceuticals INC. | $157.32 | 2023-2025 | |
| Axsome Therapeutics, INC. | $131.03 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.08 | 2019-2024 | Jardiance |
| Abbott Laboratories | $119.23 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $118.75 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.50 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $65.78 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.78 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $41.85 | 2019 | |
| Allergan, INC. | $40.25 | 2019-2020 | |
| Amarin Pharma, INC. | $35.02 | 2019 | |
| Avion Pharmaceuticals | $33.78 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $28.10 | 2019 | |
| Sanofi Pasteur INC. | $27.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.11 | 2025 | Xifaxan |
| Romark Laboratories, Lc | $20.76 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.99 | 2025 | Recorlev |
| Cequr Corporation | $17.67 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.65 | 2024 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $15.34 | 2019 | |
| Eisai INC. | $15.29 | 2019 | |
| Revance Therapeutics, INC. | $14.99 | 2024 | Daxxify |
| Scilex Pharmaceuticals INC. | $14.24 | 2019 | |
| Acerus Pharmaceuticals Corporation | $14.19 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.36 | 2019 | |
| Astellas Pharma US INC | $11.82 | 2019 | |
| Radius Health, INC. | $11.53 | 2020 | |
| Valeritas, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelli Ridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.